The Lancet. Oncology. pii: S1470-2045(21)00708-7. doi: 10.1016/S1470-2045(21)00708-7
|
Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic.
|
Pfeiler G1, DeMichele A2, Dueck AC3, Fesl C4, Gnant M5, Mayer EL6 |
 Author information
1Department of Gynecology, Medical University of Vienna, Vienna, Austria.
2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
3Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ, USA.
4Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
6Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: erica_mayer@dfci.harvard.edu.
|
Publikations ID: 35114114
Quelle: öffnen
|